Immunoassay News and Research

RSS
COVAM assay may help select convalescent plasma units for treatment of  acute COVID-19

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Toyonaka Municipal Hospital reports successful control of COVID-19

Toyonaka Municipal Hospital reports successful control of COVID-19

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

NIH provides scale-up and manufacturing support for new COVID-19 testing technologies

NIH provides scale-up and manufacturing support for new COVID-19 testing technologies

Brazilian state of Maranhão heading towards SARS-CoV-2 herd immunity, say researchers

Brazilian state of Maranhão heading towards SARS-CoV-2 herd immunity, say researchers

Promega introduces new serological antibody test for COVID-19

Promega introduces new serological antibody test for COVID-19

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

NIH invests $248.7 million in new COVID-19 testing technologies to meet U.S. demand

NIH invests $248.7 million in new COVID-19 testing technologies to meet U.S. demand

COVID-19 test kits offered by Carolina Liquid Chemistries granted FDA emergency use authorization

COVID-19 test kits offered by Carolina Liquid Chemistries granted FDA emergency use authorization

Inconsistent SARS-CoV-2 antibody results in nephrology workers

Inconsistent SARS-CoV-2 antibody results in nephrology workers

UArizona aims to develop a device for quick and accurate detection of pathogens, biological threats

UArizona aims to develop a device for quick and accurate detection of pathogens, biological threats

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

New assay improves detection of SARS-CoV-2 antibodies

New assay improves detection of SARS-CoV-2 antibodies

Study finds significant variability in the accuracy of currently available COVID-19 antibody tests

Study finds significant variability in the accuracy of currently available COVID-19 antibody tests

New technology allows quick and cost-effective identification of cancer biomarkers

New technology allows quick and cost-effective identification of cancer biomarkers

Novel antibody test for SARS-CoV-2

Novel antibody test for SARS-CoV-2

LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector

LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.